Clinical progression in alpha-synuclein positive LRRK2-PD and sporadic Parkinsons disease: a longitudinal analysis

This longitudinal analysis of propensity score-matched cohorts from the Parkinson's Progression Markers Initiative reveals that while alpha-synuclein positive LRRK2-PD patients exhibit milder baseline motor symptoms and dopaminergic deficits compared to sporadic PD, their four-year clinical progression trajectories are statistically similar.

The Gist

Imagine Parkinson's disease as a massive, chaotic construction site. For a long time, doctors thought all construction sites looked the same: they all had the same type of debris (a protein called alpha-synuclein) piling up, causing the building (the brain) to crumble at the same speed.

However, recent discoveries revealed that some construction sites are actually run by a specific "foreman" with a unique genetic instruction manual (a mutation in the LRRK2 gene). Some of these sites have the usual debris, but others are strangely clean, with no alpha-synuclein piles at all.

This new study is like a detailed inspection report comparing two specific groups of construction sites:

1. Group A: Sites run by the LRRK2 foreman that do have the alpha-synuclein debris.
2. Group B: The standard "sporadic" sites (no specific foreman) that also have the alpha-synuclein debris.

The big question was: If both groups have the same type of debris, do they crumble at the same speed?

The Setup: Leveling the Playing Field

The researchers used data from a huge, long-term project called PPMI (Parkinson's Progression Markers Initiative). To make a fair comparison, they used a statistical "matching game." They paired up patients from Group A and Group B so that they were identical in age, how long they'd had the disease, their gender, and how much medication they were taking.

Think of it like a boxing match where the referee ensures both fighters are the same weight, age, and experience level before the bell rings.

The Starting Line: Who Had the Lighter Load?

When the study began (the "baseline"), there was a clear difference in the condition of the two groups:

• The LRRK2 Group (Group A): These patients were in better shape. Their "motor scores" (how well they could move) were higher, and their brains showed less damage on imaging scans. It was as if their construction site had fewer cracks in the foundation to start with.
• The Sporadic Group (Group B): These patients started with more severe symptoms and more visible brain damage.

The Analogy: Imagine two cars starting a race. The LRRK2 car is a brand-new, high-performance sports car with a full tank of gas. The Sporadic car is a slightly older sedan that already has a few dents and a lower fuel gauge.

The Race: Do They Speed Up Differently?

The researchers then watched these two groups over four years to see how fast they declined. They tracked everything from walking ability and tremors to mood and thinking skills.

Here is the surprising result: They finished the race at almost the exact same speed.

Even though the LRRK2 group started with a "better car" (milder symptoms), they didn't slow down the rate of decline. Once the race started, the LRRK2 patients and the Sporadic patients deteriorated at the same rate. The "sports car" didn't stay ahead; it just started from a better position.

Why Does This Matter?

This finding is a game-changer for two reasons:

1. The "Debris" is the Real Driver: It suggests that once the alpha-synuclein debris is present (the "S+" status), the specific genetic foreman (LRRK2) doesn't change the speed of the collapse. The debris itself is the main engine of the disease's progression.
2. The "Clean" Sites Were the Outliers: Previous studies suggested LRRK2 patients were generally slower to decline. This study explains why: those studies likely included the "clean" sites (LRRK2 patients without the debris). Once you filter out the clean sites and only look at the ones with the debris, the LRRK2 patients behave just like everyone else.

The Bottom Line

Think of Parkinson's progression like a river flowing downhill.

• Sporadic PD is a river starting from a high, rocky mountain (severe symptoms).
• LRRK2 PD with debris is a river starting from a slightly lower hill (milder symptoms).

This study found that once the water starts flowing, the speed of the current is the same for both rivers. The starting height doesn't change the speed of the flow; the nature of the water (the alpha-synuclein) does.

The Takeaway for Patients and Doctors:
If a patient has the LRRK2 gene and shows signs of alpha-synuclein, doctors should treat their progression expectations similarly to standard Parkinson's patients. However, because they started with milder symptoms, they might have a "head start" in terms of quality of life, even if the disease moves at the same pace.

This also tells researchers that when designing new drugs or clinical trials, they need to check for this alpha-synuclein "debris" first. You can't compare apples to oranges; you have to compare apples to apples to see if a new treatment actually works.

Technical Summary

1. Problem Statement

Parkinson's disease (PD) is biologically heterogeneous. While the majority of sporadic PD (sPD) cases involve aggregated alpha-synuclein (αSyn) pathology detectable via seed amplification assay (SAA) in cerebrospinal fluid (CSF), LRRK2-associated PD (LRRK2-PD) is distinct. Approximately 30% of LRRK2-PD patients lack detectable αSyn aggregates (S-), while the remainder are S+.

Historically, LRRK2-PD has been characterized by a milder phenotype and slower progression compared to sPD. However, recent data suggests that this "milder" phenotype may be driven specifically by the S- subset of LRRK2-PD patients. The critical knowledge gap addressed in this study is whether LRRK2-PD patients who do have αSyn pathology (S+ LRRK2-PD) exhibit a different clinical trajectory compared to sPD patients with similar pathology (S+ sPD). The authors hypothesize that if αSyn is the primary driver of progression, S+ LRRK2-PD and S+ sPD should demonstrate similar longitudinal clinical trajectories despite potential baseline differences.

2. Methodology

The study utilized data from the Parkinson's Progression Markers Initiative (PPMI) cohort.

• Cohort Selection:

  • Initial pool: 165 LRRK2-PD participants and 950 sPD participants.
  • Inclusion Criteria: Confirmed LRRK2 mutation (G2019S, R1441C/G/H, N1437H, I2020T) or sPD; positive for αSyn aggregates on SAA (S+); at least one follow-up visit with levodopa equivalent dose (LED) > 0.
  • Exclusion Criteria: SAA negative status, MSA-type SAA, inconclusive SAA, presence of non-LRRK2 pathogenic variants, or insufficient follow-up (<1 year for LRRK2, <3 years for sPD).
  • Propensity Score Matching (PSM): To address inherent differences in PPMI enrollment criteria (e.g., sPD participants were often earlier in disease duration and untreated at baseline, while LRRK2 participants could be treated), a 1:1 propensity score matching was performed.
  • Matching Variables: Age, sex, disease duration, and LED.
  • Final Sample: 79 participants per group (Total N = 158).

• Statistical Analysis:

  • Baseline Comparison: Wilcoxon rank-sum tests for continuous variables and Chi-Square/Fisher's exact tests for categorical variables.
  • Longitudinal Analysis: Generalized Linear Mixed Effects (LMM) models with random intercepts and slopes were used to model trajectories over 4 years.
  • Adjustments: Models adjusted for baseline outcome values and time-varying LED.
  • Outcomes: Assessed motor scores (MDS-UPDRS I, II, III), non-motor features (cognition, depression, autonomic function), and biological markers (DAT imaging, CSF biomarkers).
  • Significance Threshold: p < 0.05 (two-tailed).

3. Key Contributions

• Stratification by Biomarker Status: This study moves beyond genetic classification alone, isolating the S+ subset of LRRK2-PD to directly compare it with S+ sPD, thereby controlling for the presence of the core proteinopathy (αSyn).
• Rigorous Matching: By employing propensity score matching on disease duration and medication status, the study mitigates confounding variables inherent in the original PPMI recruitment design, allowing for a more apples-to-apples comparison of disease progression.
• Longitudinal Focus: Unlike cross-sectional studies, this analysis tracks clinical trajectories over a 4-year period to determine if the rate of decline differs between the two groups.

4. Results

• Baseline Characteristics:

  • Clinical Severity: S+ LRRK2-PD participants presented with milder disease at baseline compared to S+ sPD.
    • Higher Modified Schwab and England scores (better function).
    • Lower MDS-UPDRS Part III (ON) scores (16 vs. 21; p=0.011).
    • Lower tremor scores (2 vs. 4; p=0.022).
    • Lower total MDS-UPDRS scores (29 vs. 34; p=0.027).
  • Imaging: S+ LRRK2-PD showed less dopaminergic deficit (higher lowest putamen ratio: 0.27 vs. 0.25; p=0.016).
  • Fluid Biomarkers: No significant differences were found in CSF amyloid beta, tau, or serum neurofilament light chain (NfL) between groups.
  • Demographics: Groups were successfully matched on age, sex, and disease duration.

• Longitudinal Progression (4-Year Follow-up):

  • Primary Finding: Despite the milder baseline presentation in the LRRK2 group, there were no statistically significant differences in the rate of clinical progression between S+ LRRK2-PD and S+ sPD.
  • Trajectories: Linear mixed models showed overlapping trajectories for motor and non-motor measures.
  • Exception: A marginal difference was observed in the rate of change for the tremor score (ON) (p=0.049), but neither group showed a statistically significant change over time individually, and the clinical relevance was deemed low.

5. Significance and Implications

• Pathophysiological Insight: The findings suggest that once αSyn pathology is present (S+), the underlying genetic driver (LRRK2 mutation) does not significantly alter the rate of clinical progression compared to sporadic cases. This supports the hypothesis that αSyn aggregation is the primary driver of disease progression in these patients, regardless of the genetic etiology.
• Re-evaluating the "Milder" Phenotype: The study confirms that the historically observed "milder" phenotype of LRRK2-PD is largely attributable to the S- subset (those without αSyn aggregates). The S+ subset behaves clinically like sporadic PD over time.
• Clinical Trial Design: The results emphasize the necessity of stratifying patients by αSyn biomarker status (SAA) in clinical trials. Including S- LRRK2 patients in a cohort intended to test αSyn-targeted therapies could dilute treatment effects, as their disease mechanism may differ fundamentally from S+ patients.
• Future Directions: The authors note limitations regarding the genetic heterogeneity of LRRK2 variants (the cohort was 96% G2019S) and the need for further study on other variants (e.g., R1441C/G) and diverse ethnic populations.

Conclusion: While S+ LRRK2-PD presents with milder motor symptoms and less dopaminergic loss at baseline, its longitudinal clinical progression is indistinguishable from S+ sporadic PD, reinforcing the central role of αSyn pathology in driving disease trajectory.